Undervalued to begin with, shows efficacy, cap raise extra cash, 'deals on table'. Possible fda partial approval late next year.. Same could happen here.
TLX Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
I88 Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”
